Study: MERCURY-3 trial results support efficacy of Roclanda
September 13th 2023MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.
ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation
September 9th 2023The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.
ASRS 2023: Which topics at the annual meeting did researchers find exciting?
September 5th 2023At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!
ASRS 2023: Presenters share fascinating research highlights from the 2023 ASRS annual meeting
September 4th 2023At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!
US FDA approves Regeneron’s aflibercept injection 8mg for treatment of DME, DR, wet AMD
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
ASRS 2023: Fernando Arevalo on retinal detachments associated to retinoschisis
August 3rd 2023Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.